Indivior Pharmaceuticals, Inc. Comprehensive Income
Indivior Pharmaceuticals, Inc. (INDV) reported Comprehensive Income of $123.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $123.00M, a 515.00% increase year-over-year.
- Indivior Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $89.00M, a 81.63% increase year-over-year.
- Indivior Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $105.00M, a 950.00% increase year-over-year.
- Indivior Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $43.00M, a 48.28% increase year-over-year.
- Indivior Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $216.00M, a 21500.00% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $1.00M.
- Indivior Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$124.00M.
- Indivior Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$50.00M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $123.00M 10-Q · filed 2026-08-03 | $212.00M 10-Q · filed 2026-08-03 | $317.00M derived: sum of 3 quarters · filed 2026-08-03 | $360.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $89.00M 10-Q · filed 2026-04-30 | $194.00M derived: sum of 2 quarters · filed 2026-04-30 | $237.00M derived: sum of 3 quarters · filed 2026-04-30 | $257.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $105.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $148.00M derived: sum of 2 quarters · filed 2026-02-26 | $168.00M derived: sum of 3 quarters · filed 2026-08-03 | $216.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $43.00M 10-Q · filed 2025-10-30 | $63.00M derived: sum of 2 quarters · filed 2026-08-03 | $111.00M 10-Q · filed 2025-10-30 | $122.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $20.00M 10-Q · filed 2026-08-03 | $69.00M 10-Q · filed 2026-08-03 | $79.00M derived: sum of 3 quarters · filed 2026-08-03 | $108.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $49.00M 10-Q · filed 2026-04-30 | $59.00M derived: sum of 2 quarters · filed 2026-04-30 | $88.00M derived: sum of 3 quarters · filed 2026-04-30 | -$9.00M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $39.00M derived: sum of 2 quarters · filed 2026-02-26 | -$58.00M derived: sum of 3 quarters · filed 2026-02-26 | $1.00M 10-K · filed 2026-02-26 | -$4.00M 10-K · filed 2025-03-03 |
| 2024-09-30 | $29.00M 10-Q · filed 2025-10-30 | -$68.00M derived: sum of 2 quarters · filed 2025-10-30 | -$9.00M 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | -$97.00M 10-Q · filed 2025-07-31 | -$38.00M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $59.00M 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | -$124.00M 10-K · filed 2026-02-26 | -$127.00M 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$50.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |